Compare Merck & Co., Inc. (MRK) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Xcel Energy Inc — how do they compare? Merck & Co., Inc. trades at $148.11 (market cap $366.28B), while Xcel Energy Inc trades at $76.24 (market cap $48.02B). The key difference: Merck & Co., Inc. is far larger — about 7.6× Xcel Energy Inc's market cap, and Xcel Energy Inc pays the higher dividend (3.08%). Which is the better fit depends on your goals.
| MRK | XEL | |
|---|---|---|
Market Cap | $366.28B | $48.02B |
Sector | Health | Utilities |
52-Week High | $156.43 | $83.91 |
52-Week Low | $77.60 | $72.05 |
Enterprise Value | $413.04B | $86.33B |
Dividend Yield | 2.29% | 3.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
XEL trades at $76.88, up 1.53% on the day, with a bearish technical signal but strong analyst consensus. Recent Q2 2026 earnings beat estimates at $0.93 per share. The company maintains solid profitability with a 15.28% net income margin and is executing a $70B+ capital investment plan through 2030 to drive growth. Dividend payments remain consistent at $0.59 quarterly.
Outlook is positive with a $92 consensus price target, though risks include high capital expenditures, regulatory scrutiny from wildfire lawsuits, and rising interest rates. The stock offers stable income and growth potential but faces execution and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
